T-E Pharma announced that its subsidiary, T-E Meds, Inc., has been shortlisted for the prestigious “Best New Drug Developer” category at the 12th World ADC Awards 2025. Selected from a highly competitive pool of global nominees, T-E Meds is one of six finalists. The winners—Champion and Runner-up—will be revealed on November 5, 2025 (Wednesday) at the World ADC San Diego conference, which draws over 1,400 participants from across the globe.
Since its launch in 2014, the World ADC Awards has become the most influential international recognition in the field of antibody-drug conjugates (ADCs), honoring breakthroughs in innovation, R&D potential, and clinical value. The “Best New Drug Developer” award specifically acknowledges ADC companies with strong development potential and assets approaching clinical stages, highlighting excellence in innovation, differentiation, and experimental data. Being shortlisted itself reflects global recognition and affirms a company’s competitive strength in ADC research and development.
Driving Innovation in ADCs and ARCs with a Leading Platform
T-E Meds, a sister company of Immunwork, is dedicated to the innovative development of ADCs and antibody-radionuclide conjugates (ARCs). Leveraging its proprietary multi-arm linker platform, the company integrates mono- and dual-drug bundles with modular conjugation chemistry to create next-generation ADCs. This platform enables product with a high drug-to-antibody ratio (DAR), high yield, high purity, and versatile payload capacity, establishing a distinctive and world-class ADC technology platform.
Core Pipeline Highlights: TE-1146 and TE-1182
● TE-1146 is the first ADC linking lenalidomide to the anti-CD38 antibody daratumumab, developed for the treatment of multiple myeloma and related indications. Preclinical studies have demonstrated superior tumor-killing efficacy compared with current drug combinations, achieving improved therapeutic outcomes at lower doses with both high potency and safety. In January 2025, T-E Meds out-licensed the commercial rights of TE-1146 in Taiwan, Southeast Asia, Australia, and New Zealand to Orient EuroPharma for NT$ 270 million (approximately USD 8.5 million). In June 2025, the program was further recognized by Taiwan’s Center for Drug Evaluation (CDE) as a key new drug development project, underscoring its market value and clinical potential. With most of the CMC development and preliminary toxicology studies already completed, T-E Meds is targeting IND submission in the first half of 2026.
● TE-1182 is a dual-payload ADC targeting HER2-expressing tumors—including breast, gastric, and lung cancers—designed to overcome tumor heterogeneity and drug resistance, particularly in HER2-low or refractory settings. Addressing an urgent clinical need, TE-1182 aims to provide more effective therapeutic options for cancer patients. The program has completed multiple key preclinical studies and is advancing toward clinical readiness, with IND submission planned for Q4 2026.
Advancing Toward the Global Stage with Breakthrough Therapies
T-E Meds’ nomination for the 12th World ADC Awards – Best New Drug Developer underscores the company’s robust innovation capabilities and growing global recognition in ADC technology and drug development. With its advanced platform and pioneering pipeline, T-E Meds remains committed to delivering breakthrough therapies, accelerating clinical advancement, and expanding its global footprint.
Reference: Shortlist for Best New Drug Developer
Shortlisted announcement: https://worldadc-awards.com/about/2025-shortlist/